HomeNDC LookupDrug shortages › Pentostatin Injection

Pentostatin Injection shortage

Pentostatin Injection is currently listed in shortage by the FDA. The FDA lists 1 affected product. The reported reason: Other. This page was last refreshed from FDA data on Sep 19, 2026.

Current ⚠ Supply risk: High Oncology 1 product 23 days First posted Aug 27, 2026 Updated Aug 27, 2026
Here’s the bottom line

Pentostatin injection (10 mg) is currently unavailable due to manufacturing delays at Pfizer, with supply not expected to return until mid-to-late 2027. No other manufacturers are listed as a source for this medicine right now.

Don’t stop or change your therapy on your own — ask your pharmacist about other manufacturers and your prescriber about a long-term plan.

Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →
1
Affected NDCs
1
Reporting manufacturers
0/1
Reporting mfrs supplying
0/1
Affected strengths supplied
100%
NDCs unavailable
23
Days in shortage
Source: FDA Drug Shortages Database API (openFDA). Last refreshed Sep 19, 2026 · yesterday

What’s in shortage — at a glance

These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Pentostatin Injection. Other makers that haven’t reported a problem are shown in the green card below.

Availability of affected NDCs
From the FDA shortage report
1 NDCs
Unavailable 1
Affected strengths still supplied
Among manufacturers reporting this shortage
0/1 strengths
No supply 1
FDA-reporting manufacturers with supply
Among manufacturers reporting this shortage
0/1 makers
No supply 1
Other manufacturers
We couldn’t automatically confirm other manufacturers of Pentostatin Injection that aren’t reporting a shortage. Ask your pharmacist whether a different manufacturer or strength can be ordered.
Shortage timeline
  1. Aug 27, 2026
    Currently in shortage
    1 of 1 product affected.
  2. Aug 27, 2026
    First reported to the FDA
    1 product first listed.

Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.

What exactly is on backorder — by manufacturer

Manufacturer: Hospira, Inc., a Pfizer Company 📞 844-646-4398 1 NDC click to expand
Status NDC / product Strength Availability Related information Reason
Current Nipent, Injection, 10 mg, single dose vial (NDC 0409-0801-01) NDC 00409-0801-01 Unavailable Next delivery: Q2 2027; Estimated recovery: Q3 2027; Shortage per manufacturer: manufacturing delays Other

These rows are manufacturer reports to the FDA for Pentostatin Injection — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Pentostatin Injection? options further down this page.

Why is Pentostatin Injection in shortage?

Right now, the 10 mg single-dose vial of Pentostatin Injection made by Hospira (a Pfizer company) is unavailable due to manufacturing delays — basically, there's a hold-up at the factory that's preventing them from getting product out the door. The FDA reason code listed is "Other," which is a broad category, but Hospira has shared that the issue comes down to those manufacturing delays.

According to the information Hospira reported, the next delivery isn't expected until sometime in the second quarter of 2027, with supply expected to recover by the third quarter of 2027. So this is expected to be an extended shortage for this particular product from this manufacturer.

FDA reason code(s): Other

Based on the manufacturer-reported reason(s) and notes on file with the FDA for Pentostatin Injection, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.

What should I do if I take Pentostatin Injection?

Pentostatin injection is currently on the FDA drug-shortage list, and I want to walk you through what that means for you.

There is only one strength involved here, the 10 mg single-dose vial, and it is the strength that is affected. Right now that strength has no reported available source from the manufacturer on this record. The reason given is listed simply as "Other," with the maker also noting manufacturing delays. The manufacturer's timeline points to a next delivery in the second quarter of 2027 and an estimated recovery in the third quarter of 2027, so this may take some time to resolve.

Please keep in mind this report reflects only the manufacturer that filed it, and it may not match what your own pharmacy or treatment center actually has in stock.

Here is what I suggest:

  • Do not stop, skip, or change your treatment on your own. Pentostatin is given as part of a care plan, so any change should come from your care team.
  • Ask your pharmacy or infusion center to check with wholesalers and other suppliers for the 10 mg vial.
  • Because the same medicine isn't listed from another maker in our records, talk with your prescriber about how to manage your treatment schedule if the vial cannot be found.

Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls.

If you are a patient:
  • Don’t stop or change the medication on your own — talk to your prescriber first.
  • If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
  • Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
  • Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Keep reading
Our full Pentostatin Injection guide

Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.

Read the Pentostatin Injection guide →
Therapeutic equivalents & pricing 1 productclick to expand

Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.

ProductManufacturerPackageNADAC $/unitAB ratingAvailability
Nipent 2 mg/mLNDC 00409-0801-01 Hospira, 1 vial AP FDA listed

Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.

Other drugs in the same treatment class

These are different medicines — not other versions of Pentostatin Injection — that fall in the same broad treatment class (antineoplastic - antimetabolites) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.

Identity & classification

GCN Seq No 016510
GCN 19901
HICL code 006301
Ingredient (HICL) Pentostatin
HIC1 code V
Therapeutic class — broad (HIC1) Neoplasms
HIC2 code V1
Therapeutic class — intermediate (HIC2) Antineoplastic Drugs
HIC3 code V1B
Therapeutic class — specific (HIC3) Antineoplastic - Antimetabolites
AHFS code 10:00.00.00
AHFS class Antineoplastic Agents
FDB label name NIPENT 10 MG VIAL
FDB brand name Nipent
Legend status F — Federal legend — prescription drug or device
GPI-1421700045002120
Where does this data come from?
Identity codes come from First Databank (FDB) (HICL ingredient, HIC1–3 therapeutic-class hierarchy, GCN, AHFS class, legend status) and Medi-Span GPI, mapped from a representative affected NDC. Licensed reference data — for identification only.

Other oncology shortages

Pentostatin Injection shortage FAQs

Is Pentostatin Injection in shortage?
Yes — the FDA currently lists Pentostatin Injection in shortage (status: “Current”, first reported Aug 27, 2026). 1 of 1 product is affected. This is national, manufacturer-reported data, so your pharmacy may still have stock.
Why is Pentostatin Injection in shortage?
The manufacturer-reported reason on file with the FDA: Other.
Which products are affected?
Nipent, Injection, 10 mg, single dose vial (NDC 0409-0801-01) (NDC 00409-0801-01). The full per-NDC list (availability, manufacturer and status) is in the table above — each NDC links to its own page.
When will Pentostatin Injection be available again?
The FDA does not publish a guaranteed restock date, and no estimated-recovery note is on file. Availability can change daily — confirm with your pharmacy.
What should I do if I take Pentostatin Injection?
Don’t stop or change it on your own. Ask your pharmacist whether they can order it from another manufacturer or a different strength/package size, and ask your prescriber about a long-term plan before your supply runs out.

Still have a question about the Pentostatin Injection shortage?

Ask a pharmacist about this shortage →
How to read the Supply-Risk rating
Low (1–2)Multiple manufacturers still supplying and most strengths or pack sizes sourceable.
Medium (3)Some constraint — fewer suppliers or a notable share of NDCs unavailable.
High (4–5)Down to a single source, most strengths or pack sizes unsourceable, or a long-running outage.
Where does this data come from?
Shortage records come from the FDA Drug Shortages Database API via openFDA (/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.
Data structure & sourcing designed and verified by Dr. Brian Staiger, PharmD.
← Back to all current drug shortages